LifeKit Preven gets FDA breakthrough device identified as testing for early colon cancer

Colorectal cancer (CRC) is one of the most common types of cancer in the United States, with more than 130,000 new cases each year, of which about 50,000 dieMedical institutions across the United States perform more than 14 million colonoscopies each year, at a cost of more than $14 billion for CRC diagnosis and treatmentBut data show that two-thirds of Americans ignore CRC screening guidelines, and 60 percent of CRC cases are not diagnosed until later in the diseaseLifeKit Preven is the first non-invasive colon cancer diagnostic device identified by the FDA's breakthrough device, primarily for precancerous polyps testing and early colon cancer diagnosisUnlike other non-invasive testing devices on the market, the device does not rely on colonoscopy and is able to directly detect precancerous adenomas in patientsnon-invasive testing equipment increases patient compliance with CRC screening programsIt is estimated that the promotion of CRC screening could save more than 10,000 lives in the United States each yearclinical studies have shown that LifeKit Prevent is very accurate in detecting colon cancer and precancerous adenomas and may be more convenient and reliable than existing CRC diagnostic testing techniquesDiagnosis based on the device will lead to colonoscopy screening for patients at high risk of resistance treatment, screening for precancerous adenomas and preventing their further deterioration into cancer, thereby reducing CRC morbidity and mortalityNote: The original text has a limitation